Truist Lifts PT on Immunovant, Inc. (IMVT) But Maintains a Hold Rating

Immunovant, Inc. (NASDAQ:IMVT) is one of the best momentum stocks to buy according to analysts. Truist lifted the price target on Immunovant, Inc. (NASDAQ:IMVT) to $30 from $23 on May 22, maintaining a Hold rating on the shares. The firm told investors in a research note that it updated its model after the company reported fiscal year 2026 results, and after it incorporated modest RA contribution with 10% probability of success based on the previous day’s IMVT-1402 data.

Is Immunovant, Inc. (IMVT) The Most Undervalued Stock With Smart Money Ratings?

In its financial results for fiscal Q4 ended March 31, 2026, Immunovant, Inc. (NASDAQ:IMVT) reported that its cash and cash equivalents as of the end of the quarter totaled approximately $902.1 million, which provides runway for announced indications through the potential commercial launch of IMVT-1402 in GD. The company’s research and development expenses for the quarter were $142.3 million compared to $93.7 million for the prior year period, driven by activities related to its clinical trials of IMVT-1402 and $39.0 million related to contractual costs recognized in connection with the discontinuation of batoclimab.

Immunovant, Inc. (NASDAQ:IMVT) develops treatments for autoimmune diseases. Its product pipeline includes IMVT-1402, which is a novel fully human monoclonal antibody targeting the neonatal fragment crystallizable receptor (FcRn).

While we acknowledge the risk and potential of IMVT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IMVT and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 15 Stocks That Will Make You Rich in 10 Years AND 12 Best Stocks That Will Always Grow.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1